-
ABT-888 (Veliparib) Experimental Workflows
2026-08-15
ABT-888 (Veliparib) provides a selective PARP1/2 perturbation tool for testing DNA repair inhibition, chemotherapy sensitization, and radiation response. This workflow connects formulation control with combination assays in colorectal cancer, MSI tumor models, and replication-stressed ovarian cancer systems.
-
Cisplatin (CDDP) Workflows for Cancer Research
2026-08-14
Build reproducible Cisplatin workflows that connect DNA crosslinking to viability, apoptosis, ROS, and chemotherapy resistance readouts. This guide also translates a recent cholangiocarcinoma metabolism study into practical combination-testing and xenograft design choices.
-
Nilotinib Workflows for Kinase and Tumor Immunology
2026-08-14
Nilotinib (AMN-107) provides a practical way to interrogate BCR-ABL, KIT, and PDGFR signaling while opening a distinct preclinical route into tumor-immunity assays. This guide connects phosphoprotein analysis, viability testing, MHC-I measurements, and combination studies into reproducible workflows with troubleshooting guidance.
-
Sulfo-NHS-SS-Biotin for Cleavable Protein Labeling
2026-08-13
Sulfo-NHS-SS-Biotin is a water-compatible, amine-reactive reagent for labeling lysine side chains, N-terminal amines, and accessible cell-surface proteins. Its reducible disulfide spacer supports affinity capture followed by label removal, making it useful for reversible protein purification and surface-trafficking studies.
-
LTI6426–Panobinostat Combination in Myeloma
2026-08-13
The reference study shows that the orally bioavailable PDI inhibitor LTI6426 can substantially enhance low-dose panobinostat activity in multiple myeloma models, including a proteasome inhibitor-resistant setting. Its mechanistic analysis links the combination to convergent endoplasmic reticulum stress signaling and identifies ATF3, DDIT3/CHOP, and DNAJB1 as candidate pharmacodynamic biomarkers.
-
Mouse Neutrophil Cell Isolation Kit: Workflow & Uses
2026-08-12
Build fast, low-perturbation neutrophil workflows for tumor immunology, nanoparticle studies, and functional assays. This guide shows how negative selection with CS1009 can support high-purity cell recovery while preserving the phenotype needed to evaluate neutrophil-targeted mRNA therapies.
-
WNT5a/GSK3/β-Catenin Controls FAP Adipogenesis
2026-08-12
The reference study identifies a WNT5a/GSK3/β-catenin circuit that restrains adipogenic conversion of skeletal muscle fibro/adipogenic progenitors (FAPs). By combining pharmacology, mass cytometry, transcriptomics, network modeling, and mouse injury models, it connects pathway modulation with reduced fatty degeneration and improved satellite-cell-supported regeneration.
-
Dual Luciferase Assay System: Reliable Workflows
2026-08-11
Learn how Dual Luciferase Assay System SKU K1136 can reduce interpretive uncertainty in mammalian gene expression experiments through paired firefly/Renilla normalization, direct-addition workflows, and defined media compatibility. Scenario-based guidance connects assay design with viability, cytotoxicity, and mechanistic studies.
-
Deferiprone as an Iron-Stress Assay Probe
2026-08-11
Deferiprone enables controlled modeling of intracellular iron deficiency, metabolic rewiring, and recovery. This article translates enterocyte metabolomics findings into practical assay decisions while distinguishing mechanistic evidence from applications in cancer biology and vascular research.
-
Canagliflozin Hemihydrate in Metabolic Research
2026-08-10
Canagliflozin hemihydrate provides a practical SGLT2-centered tool for studying renal glucose reabsorption inhibition, cellular glucose handling, and metabolic phenotypes. Its value is clearest when paired with orthogonal transport assays and used as a mechanistic contrast—not as an assumed mTOR inhibitor—in drug-sensitized yeast workflows.
-
4-MUG: A Translational Readout for GCase mRNA Therapy
2026-08-09
4-Methylumbelliferyl-β-D-Glucopyranoside, or 4-MUG, connects enzyme biochemistry with translational Gaucher disease research. This article examines how a fluorogenic β-glucosidase substrate can help evaluate optimized GBA1 mRNA, lysosomal glucocerebrosidase activity, and the evidentiary gap between catalytic rescue and disease modification.
-
Annexin V-Cy5: Apoptosis vs Lysosomal Stress
2026-08-08
The Annexin V-Cy5 Apoptosis Kit helps separate phosphatidylserine exposure from lysosomal dysfunction in microglia. This guide presents an interpretation-first workflow grounded in a reversible zebrafish model of mestranol-induced lysosomal stress.
-
RSL3: GPX4 Inhibitor for Ferroptosis Research
2026-08-07
RSL3 enables direct GPX4 inhibition to test ferroptosis, lipid peroxidation, and redox vulnerabilities in cancer models. This practical guide connects RSL3 dosing, PERK–SLC7A11 biology, oncogenic RAS synthetic lethality, and assay troubleshooting.
-
Bafilomycin A1: Precision V-ATPase Inhibitor for Lysosomal R
2026-08-07
Bafilomycin A1 delivers unmatched precision in modulating vacuolar H+-ATPase activity, empowering researchers to dissect lysosomal function, intracellular pH, and autophagic flux. Explore advanced workflows, troubleshooting tips, and actionable parameters to maximize reproducibility in cell biology and disease models.
-
Gly-Gly-Phe-Gly (GGFG): Enabling Precision in Epigenetic Dru
2026-08-06
Explore how the GGFG peptide advances drug conjugation research by bridging peptide engineering with innovative epigenetic therapies. This article uncovers technical insights and unique applications of Gly-Gly-Phe-Gly, setting it apart in the landscape of flexible linker peptides.